Kazia calls for greater awareness of the most lethal women's disease in Australia
SYDNEY, May 8, 2019 /PRNewswire/ -- This World Ovarian Cancer Day, Australian oncology-focused biotech company Kazia Therapeutics Ltd (ASX: KZA, NASDAQ: KZIA) calls for greater awareness of what is the most lethal women's disease in Australia. Every year, approximately 1,600 Australian women are...
Kazia Presents Positive Cantrixil Phase I Data at AACR Conference
SYDNEY, April 1, 2019 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to provide investors with a poster presentation summarising data from Part A of the ongoing phase I study of Cantrixil (TRX-E-002-1) in ovari...
Kazia to present on Cantrixil at American Association for Cancer Research (AACR) 2019 Annual Meeting
SYDNEY, March 25, 2019 /PRNewswire/ -- Australian oncology-focused biotech company Kazia Therapeutics Ltd (ASX: KZA, NASDAQ: KZIA) has been selected to present data from the Phase I study of Cantrixil in ovarian cancer at the American Association for Cancer Research (AACR) 2019 Annual Meeting. A...
Kazia Share Purchase Plan Raises A$0.8 Million, Taking Total Funds Raised to A$4.2 Million
SYDNEY, Nov. 20, 2018 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that the Share Purchase Plan (SPP), as described in the SPP booklet dated23 October 2018, has now been successfully completed. T...
Progress Update on GDC-0084 Program
SYDNEY, Oct. 29, 2018 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to provide an update to shareholders regarding progress with GDC-0084, which is currently in human trials for glioblastoma and several other ...
Kazia Enters Clinical Collaboration to Investigate Use of Brain Cancer Drug GDC-0084 in Breast Cancer
SYDNEY, Oct. 22, 2018 /PRNewswire/ -- The Australian oncology-focused biotech
Kazia Therapeuticsannounced today
Kazia Raises A$3.4 Million to Progress R&D Programs
SYDNEY, Oct. 18, 2018 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce the completion of a placement of KZA shares, primarily to sector-specialist institutional investors inAustralia and international...
Cantrixil Phase I Study Progresses To Next Stage
SYDNEY, Oct. 10, 2018 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce the successful completion of Part A, the dose escalation component, of its phase I study of Cantrixil in ovarian cancer. After ...
Kazia Releases Preliminary Cantrixil Phase I Data
SYDNEY, June 19, 2018 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to provide an interim update to shareholders regarding its phase I clinical trial of Cantrixil (TRX-E-002-1) in relapsed or recurrent ovarian...
Commencement Of Phase II Clinical Study Of GDC-0084
SYDNEY, March 28, 2018 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology drug development company, is pleased to announce commencement of an international phase II clinical trial of its lead program, GDC-0084. Key Points * First site, Stephenson Cance...
Kazia Receives FDA Orphan Designation for GDC-0084
SYDNEY, Feb. 23, 2018 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Kazia's investigational ne...
